Cart
0
Get 20% Free Customization In This Report
Buy this report from - $4176

Cancer Immunotherapy Market by Technology (Monoclonal Antibodies, Cytokines & Immunomodulators, and Others), by Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Head & Neck Cancer, and Others) by End User (Hospitals, Cancer Research Centers, and Clinics) - Global Opportunity Analysis and Industry Forecast, 2014-2022

LI_172244
Pages: 150
May 2017 | 2839 Views
face gplus_n
Author's : Abha Thakur
Tables: 43
Charts: 34
twit_n pr_n

Cancer Immunotherapy Market Overview:

Global Cancer Immunotherapy Market is accounted for $45,471 million in 2015, and is estimated to reach $117,114 million by 2022, growing at a CAGR of 14.5% during the analysis period (2016-2022). Cancer immunotherapy is a type of cancer treatment that boosts the human bodys natural immune system to fight against the cancer cells. This therapy is provided to cancer patients to stop the spread of cancer, to slow down the growth of cancer cells, and to improve the natural immunity for destroying the cancer cells.

The key factors that drive the growth of cancer immunotherapy market include rise in incidence & prevalence of cancer, technological advancements in treatment therapies, increase in number of R&D for the treatment of cancer, and specificity & effectiveness of cancer immunotherapy for the treatment of wide range of cancers such as lung cancer, breast cancer, skin cancer, and others. In addition, the rise in healthcare expenditure and healthcare insurance are expected to fuel the market growth during the analysis period. However, shortage of experienced healthcare professionals and lack of awareness among the population restrict the growth.

Cancer Immunotherapy Market Segmentation

Cancer Immunotherapy Market Segmentation

Segment Review

Based on technology, the global cancer immunotherapy market is categorized into monoclonal antibodies, cytokines & immunomodulators, and other technologies. Monoclonal antibodies held the highest market share and are expected to grow with the highest growth rate during the forecast period. The rise in adoption of monoclonal antibodies for the treatment of wide range of cancer such as breast cancer, lymphoma, lung cancer, brain cancer, cervical cancer, and others is the key trend that drives the market. Based on application lung cancer dominated the market in 2015 owing to the high incidence rate of lung cancer. According to global cancer statistics, among all the cancer diagnosed, lung cancer holds the highest share of 13% in 2012. By end-user, hospital sector captured the highest market share in 2015, owing to the large number of patients being treated in hospitals for cancer immunotherapy.

Geographic Review:

Geographically, the global cancer immunotherapy market is segmented into North America, Europe, Asia-Pacific, and LAMEA. North America held the largest share of the market in 2015, followed by Europe. On the other hand, Asia is anticipated to be the fastest-growing regional segment during the analysis period. The key factors that drive the growth of this market include increase in pool of patient population, rise in prevalence of different types of cancer, and rise in government investments for R&D and the healthcare reforms for the treatment of cancer. Asia-Pacific is expected to emerge as the area with maximum growth potential due to focus of key players in the emerging economies and improving healthcare infrastructure.

Worldwide Incidence of Cancer By Type 2012, (Million)

Worldwide Incidence of Cancer By Type 2012, (Million)

The global population witnessed an alarming surge in diagnosed cancer cases. For instance, according to GLOBOCAN, 14.1 million new cancer cases were diagnosed worldwide in 2012. According to WHO, the growth in cancer incidence is expected to increase by 70% over the next two decades with 22 million new cancer cases. Cancer is highly prevalent in lower and middle income countries as they lack suitable healthcare infrastructure to effectively combat the condition. For instance, according to GLOBOCAN, 57% of 14.1 million new cancer patients diagnosed worldwide in 2012 were from less developed regions. Similarly, 65% of the total worldwide death related to cancer were reported from less developed regions.

Key Market Benefits:

  • The study provides an in-depth analysis of the cancer immunotherapy market with current trends and future estimations to elucidate the imminent investment pockets
  • The report provides a quantitative analysis from 2014 to 2022 to enable the stakeholders capitalize on prevailing market opportunities
  • Extensive analysis by technology and application helps understand various trends and prevailing opportunities in the respective market
  • Comprehensive analysis of all geographical regions is provided, which determines the main opportunities in these geographies
  • Key market players within the market are profiled in this report and their strategies are analyzed thoroughly, which predict the competitive outlook of the global cancer immunotherapy market

Cancer Immunotherapy Market Key Segment:

By Technology

  • Monoclonal Antibodies
  • Cytokines & Immunomodulators
  • Others (Immune Checkpoint Inhibitors, Cell Therapy, Oncolytic Virus Immunotherapy)

By Application

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Melanoma
  • Prostate Cancer
  • Head & Neck Cancer
  • Others (Renal Cell Carcinoma, Cervical, Gastric, and Lymphoma)

By End-user

  • Hospitals
  • Cancer Research Centers
  • Clinics

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

Major companies operating in this market have adopted collaboration and partnership as their key development strategy. Companies profiled in this market includes, F. Hoffmann-La Roche AG, Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, Bayer AG, Immunomedics Inc., and Astrazeneca plc.

The other players (the profiles of these players are not covered in the report) in the value chain include Seattle Genetics, Peregrine Pharmaceuticals, Amgen Inc., and Viralytics Ltd.

 

Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENT
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research

1.5. ANALYST TOOLS AND MODELS

Chapter: 2 EXECUTIVE SUMMARY

2.1. KEY FINDINGS OF THE STUDY
2.2. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. PORTERS FIVE FORCES ANALYSIS

3.3.1. Bargaining power of buyers
3.3.2. Bargaining power of suppliers
3.3.3. Threat of substitutes
3.3.4. Threat of new entrants
3.3.5. Competitive rivalry

3.4. MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY MARKET, 2015
3.5. MARKET DYNAMICS

3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities

Chapter: 4 CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY

4.1. OVERVIEW

4.1.1. Market Size and Forecast

4.2. MONOCLONAL ANTIBODIES

4.2.1. Key Market Trends
4.2.2. Key Growth Factors and Opportunities
4.2.3. Market Size and Forecast

4.4. CYTOKINES & IMMUNOMODULATORS

4.4.1. Key Market Trends
4.4.2. Key Growth Factors And Opportunities
4.4.3. Market Size And Forecast

4.5. OTHER TECHNOLOGY

4.5.1. Key Market Trends
4.5.2. Key Growth Factors And Opportunities
4.5.3. Market Size And Forecast

Chapter: 5 CANCER IMMUNOTHERAPY MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. LUNG CANCER

5.2.1. Market size and forecast

5.3. BREAST CANCER

5.3.1. Market size and forecast

5.4. COLORECTAL CANCER

5.4.1. Market size and forecast

5.5. MELANOMA

5.5.1. Market size and forecast

5.6. PROSTATE CANCER

5.6.1. Market size and forecast

5.7. HEAD & NECK CANCER

5.7.1. Market size and forecast

5.8. OTHER CANCER

5.8.1. Market size and forecast

Chapter: 6 CANCER IMMUNOTHERAPY MARKET, BY END USER

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITAL

6.2.1. Market size and forecast

6.3. CANCER RESEARCH CENTERS

6.3.1. Market size and forecast

6.4. CLINICS

6.4.1. Market size and forecast

Chapter: 7 MULTIPLEX ASSAYS MARKET, BY GEOGRAPHY

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast
7.2.4. U.S. market size and forecast
7.2.5. Canada market size and forecast
7.2.6. Mexico market size and forecast

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast
7.3.4. Germany market size and forecast
7.3.5. France market size and forecast
7.3.6. UK market size and forecast
7.3.7. Italy market size and forecast
7.3.8. Spain market size and forecast
7.3.9. Rest of Europe market size and forecast

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities.
7.4.3. Market size and forecast
7.4.4. Japan market size and forecast
7.4.5. China market size and forecast
7.4.6. India market size and forecast
7.4.7. Rest of Asia-Pacific market size and forecast

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast
7.5.4. Latin America market size and forecast
7.5.5. Middle East market size and forecast
7.5.6. Africa market size and forecast

Chapter: 8 COMPANY PROFILES

8.1. AMGEN INC.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. ADVAXIS INC.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. MERCK & CO., INC.

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. ELI LILLY AND COMPANY

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. BRISTOL-MYERS SQUIBB COMPANY

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. PFIZER INC.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. NOVARTIS AG

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. BAYER AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. IMMUNOMEDICS INC.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. ASTRAZENECA PLC.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments

LIST OF TABLES

TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 2. GLOBAL CANCER MONOCLONAL ANTIBODIES MARKET, FOR, BY REGION, 2014-2022, ($MILLION)
TABLE 3. GLOBAL CANCER CYTOKINES & IMMUNOMODULATORS MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 4. GLOBAL OTHER CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR LUNG CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR BREAST CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR COLORECTAL CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR MELANOMA, BY REGION, 2014-2022, ($MILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR PROSTATE CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HEAD & NECK CANCER, BY REGION, 2014-2022, ($MILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR OTHER CANCERS, BY REGION, 2014-2022, ($MILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY END-USER, 2014-2022, ($MILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR HOSPITALS, BY REGION, 2014-2022, ($MILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CANCER RESEARCH CENTRES, BY REGION, 2014-2022, ($MILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET, FOR CLINICS, BY REGION, 2014-2022, ($MILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET, BY REGION, 2014-2022, ($MILLION)
TABLE 18. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 19. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 20. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 21. CANCER IMMUNOTHERAPY MARKET, FOR NORTH AMERICA, BY END-USER, 2014-2022, ($MILLION)
TABLE 22. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 23. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 24. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 25. CANCER IMMUNOTHERAPY MARKET, FOR EUROPE, BY END-USER, 2014-2022, ($MILLION)
TABLE 26. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 27. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 28. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 29. CANCER IMMUNOTHERAPY MARKET, FOR ASIA-PACIFIC, BY END-USER, 2014-2022, ($MILLION)
TABLE 30. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY COUNTRY, 2014-2022, ($MILLION)
TABLE 31. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY TECHNOLOGY, 2014-2022, ($MILLION)
TABLE 32. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY APPLICATION, 2014-2022, ($MILLION)
TABLE 33. CANCER IMMUNOTHERAPY MARKET, FOR LAMEA, BY END-USER, 2014-2022, ($MILLION)
TABLE 34. AMGEN INC. - COMPANY SNAPSHOT
TABLE 35. ADVAXIS INC. - COMPANY SNAPSHOT
TABLE 36. MERCK & CO., INC. - COMPANY SNAPSHOT
TABLE 37. ELI LILLY AND COMPANY - COMPANY SNAPSHOT
TABLE 38. BRISTOL-MYERS SQUIBB COMPANY - COMPANY SNAPSHOT
TABLE 39. PFIZER INC. - COMPANY SNAPSHOT
TABLE 40. NOVARTIS AG - COMPANY SNAPSHOT
TABLE 41. BAYER AG - COMPANY SNAPSHOT
TABLE 42. IMMUNOMEDICS INC. - COMPANY SNAPSHOT
TABLE 43. ASTRAZENECA PLC. - COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1.CANCER IMMUNOTHERAPY: MARKET SEGMENTSTION
FIGURE 2.TOP INVESTMENT POCKETS
FIGURE 3.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION,(2014 2016)
FIGURE 4.TOP WINNING STRATEGIES: NATURE AND TYPE
FIGURE 5.MARKET SHARE ANALYSIS OF CANCER IMMUNOTHERAPY, 2015
FIGURE 6.CANCER IMMUNOTHERAPY: MONOCLONAL ANTIBODIES MARKET, 2014-2022, ($MILLION)
FIGURE 7.CANCER IMMUNOTHERAPY: CYTOKINES & IMMUNOMODULATORS MARKET, 2014-2022, ($MILLION)
FIGURE 8.CANCER IMMUNOTHERAPY: OTHERS THERAPIES MARKET, 2014-2022, ($MILLION)
FIGURE 9.CANCER IMMUNOTHERAPY: LUNG CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 10.CANCER IMMUNOTHERAPY: BREAST CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 11.CANCER IMMUNOTHERAPY: COLORECTAL CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 12.CANCER IMMUNOTHERAPY: MELANOMA MARKET, 2014-2022, ($MILLION)
FIGURE 13.CANCER IMMUNOTHERAPY: PROSTATE CANCER MARKET, 2014-2022, ($MILLION)
FIGURE 14.CANCER IMMUNOTHERAPY: HEAD & NECK CANCERMARKET, 2014-2022, ($MILLION)
FIGURE 15.CANCER IMMUNOTHERAPY: OTHER CANCERS MARKET, 2014-2022, ($MILLION)
FIGURE 16.CANCER IMMUNOTHERAPY: HOSPITALS MARKET, 2014-2022, ($MILLION)
FIGURE 17.CANCER IMMUNOTHERAPY: CANCER RESEARCH CENTRES MARKET, 2014-2022, ($MILLION)
FIGURE 18.CANCER IMMUNOTHERAPY: CLINICS MARKET, 2014-2022, ($MILLION)
FIGURE 19.CANCER IMMUNOTHERAPY: U.S. MARKET, 2014-2022, ($MILLION)
FIGURE 20.CANCER IMMUNOTHERAPY: CANADA MARKET, 2014-2022, ($MILLION)
FIGURE 21.CANCER IMMUNOTHERAPY: MEXICO MARKET, 2014-2022, ($MILLION)
FIGURE 22.CANCER IMMUNOTHERAPY: UK MARKET, 2014-2022, ($MILLION)
FIGURE 23.CANCER IMMUNOTHERAPY: GERMANY MARKET, 2014-2022, ($MILLION)
FIGURE 24.CANCER IMMUNOTHERAPY: FRANCE MARKET, 2014-2022, ($MILLION)
FIGURE 25.CANCER IMMUNOTHERAPY: SPAIN MARKET, 2014-2022, ($MILLION)
FIGURE 26.CANCER IMMUNOTHERAPY: ITALY MARKET, 2014-2022, ($MILLION)
FIGURE 27.CANCER IMMUNOTHERAPY: REST OF EUROPE MARKET, 2014-2022, ($MILLION)
FIGURE 28.CANCER IMMUNOTHERAPY: CHINA MARKET, 2014-2022, ($MILLION)
FIGURE 29.CANCER IMMUNOTHERAPY: JAPAN MARKET, 2014-2022, ($MILLION)
FIGURE 30.CANCER IMMUNOTHERAPY: INDIA MARKET, 2014-2022, ($MILLION)
FIGURE 31.CANCER IMMUNOTHERAPY: REST OF ASIA-PACIFIC MARKET, 2014-2022, ($MILLION)
FIGURE 32.CANCER IMMUNOTHERAPY: LATIN AMERICA MARKET, 2014-2022, ($MILLION)
FIGURE 33.CANCER IMMUNOTHERAPY: MIDDLE EAST MARKET, 2014-2022, ($MILLION)
FIGURE 34.CANCER IMMUNOTHERAPY: AFRICA MARKET, 2014-2022, ($MILLION)

 

Cancer immunotherapy is the type of cancer treatment that helps the immune system fight against cancer. There are different types of cancer immunotherapy used, such as monoclonal antibody, therapeutic cancer vaccines, checkpoint inhibitors, cytokines, and others. Increase in pool of patient population suffering from different types of cancer such as lung cancer, breast cancer, ovarian cancer, and other majorly drive the global cancer immunotherapy market. In addition, rise in geriatric population and increase in healthcare expenditure by the government boosts the market. North America held the highest market share in 2015. Ample government funds for the R&D related to cancer treatment and increase in prevalence of cancer drive the growth of the North American cancer immunotherapy market.

Asia-Pacific has the highest market potential due to rise in incidence of cancer, growth in per capita income in many countries in the region such as India and China, government initiatives for the improvement of healthcare sector, and rise in focus of leading manufacturers on expanding their geographic presence in emerging Asia-Pacific countries to capture high growth opportunities in the market. Major companies involved in the cancer immunotherapy market are Amgen Inc., Advaxis Inc., Merck & Co., Inc., Eli Lilly and Company, and others.

 

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

 
 

PURCHASE OPTIONS

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,    Int'l : +1-503-894-6022
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry
 
 

Purchase Full Report of
Cancer Immunotherapy Market- Global Opportunity Analysis and Industry Forecast, 2014-2022

  • Online Only
  • $4176
  • Online cloud Access only
  • Restected Print, copy, paste,download
  • Read Only
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Data Pack
  • $4640
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Single User
  • $5540
  • Restricted to one authorized users
  • One print only
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Five User
  • $6654
  • Limited to 5 authorized users
  • Print Upto Five Copies
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  •   Free quartery industry update
  •   Free report update (Within 180 days)
  •   Subscription Model Sign In
  • Enterprice
    License/PDF

  • $9280
  • Unlimited within company/enterprise
  • Unlimited within company/enterprise
  • Available in Excel & PDF
  • 20% free customization (Pre-Sale)
  • Free quartery industry update
  • Free report update (Within 180 days)
  • Subscription Model Sign In

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 
 

FREQUENTLY ASKED
QUESTIONS?

 
 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 
 
 

Why Allied Market Research

 

Infallible Methodology

To ensure high level data integrity, accurate analysis and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 
 

Featured Readings

 

Get Fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts